Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

Surgery Today

Volumn 45, Issue 10, 2015, Pages 1263-1270

  Iwata, Takekazu ^a   Yoshida, Shigetoshi ^a   Nagato, Kaoru ^a   Nakajima, Takahiro ^a   Suzuki, Hidemi ^a   Tagawa, Tetsuzo ^a   Mizobuchi, Teruaki ^a   Ota, Satoshi ^a   Nakatani, Yukio ^a   Yoshino, Ichiro ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute exacerbation; Idiopathic pulmonary fibrosis; Lung cancer; Pirfenidone; Surgery

Indexed keywords

AMINOTRANSFERASE; KREBS VON DEN LUNGEN 6; PIRFENIDONE; PROTEIN; UNCLASSIFIED DRUG; ANTIFIBRINOLYTIC AGENT; PYRIDONE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEASIBILITY STUDY; FEMALE; FIBROSING ALVEOLITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOBECTOMY; LUNG CANCER; LUNG DISEASE; LUNG FISTULA; LUNG FUNCTION; LUNG RESECTION; MALE; NAUSEA; OPERATION DURATION; PERIOPERATIVE PERIOD; PHOTOSENSITIVITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; RETROSPECTIVE STUDY; SIDE EFFECT; SUPRAVENTRICULAR TACHYCARDIA; SURGICAL INFECTION; TREATMENT OUTCOME; WEDGE RESECTION; WOUND COMPLICATION; ACUTE DISEASE; COMPARATIVE STUDY; COMPLICATION; IDIOPATHIC PULMONARY FIBROSIS; LUNG NEOPLASMS; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; VERY ELDERLY;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIFIBRINOLYTIC AGENTS; DISEASE PROGRESSION; FEASIBILITY STUDIES; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PERIOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PYRIDONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84941413610     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-014-1071-5     Document Type: Article

References (36)

1. Saito Y, Kawai Y, Takahashi N, Ikeya T, Murai K, Kawabata Y, et al. Survival after surgery for pathologic stage IA non-small cell lung cancer associated with idiopathic pulmonary fibrosis. Ann Thorac Surg. 2011;92:1812–7.
2. Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis? J Thorac Cardiovasc Surg. 2008;136:1357–63.
3. Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med. 2000;161:5–8.
4. Yoshimura K, Miyamoto A, Uruga H, Morokawa N, Beika Y, Kishi K. A nation-wide survey on prophylaxis for acute exacerbation of idiopathic pulmonary fibrosis following lung surgery for associated lung cancer (in Japanese with English abstract). The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2008. 2009:77–81.
5. Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005;171:1040–7.
6. King TE Jr, Bradfold WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, ASCEND Study Group, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370:2083–92.
7. Collard HR, Moore BB, Flaherty KR, Brown KK, Kaner RJ, King TE Jr, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176:636–43.
8. Kawabata Y, Hoshi E, Ubukata M, Takayanagi N, Sugita Y, Aoyama K, et al. Histological changes are background factors in acute exacerbation of usual interstitial pneumonia pattern/lesions following lung resection (in Japanese with English abstract). Haigan (Jpn J Lung Cancer). 2006;46:329–36.
9. Matsubara O, Ohba T, Ninomiya H, Ishikawa Y, Mark E. Histological characteristics in the prediction of acute exacerbation of idiopathic pulmonary fibrosis (IPF) following surgery for primary lung cancer. Mod Pathol. 2009;22:358A.
10. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788–824.
11. Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137:129–37.
12. Harris JM, Johnston ID, Rudd R, Taylor AJ, Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax. 2010;65:70–6.
13. Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88:396–404.
14. Chiba H, Natsuzaka M, Shiratori M, Mori M, Takahashi H. Epidemiological survey of patients with idiopathic interstitial pneumonias using clinical personal records in Hokkaido (in Japanese with English abstract). The Annual Report by Study Group of Ministry of Health and Welfare for Diffuse Lung Disease. Diffuse Lung Diseases Research Group from the Ministry of Health, Labour and Welfare of Japanese Government 2010. 2011:143–51.
15. Watanabe N, Taniguchi H, Kondoh Y, Kimura T, Kataoka K, Nishiyama O, et al. Efficacy of chemotherapy for advanced non-small cell lung cancer with idiopathic pulmonary fibrosis. Respiration. 2013;85:326–31.
16. Amano J, Kuwano H, Yokomise H. Thoracic and cardiovascular surgery in Japan during 2011: annual report by The Japanese Association for Thoracic Surgery. Gen Thorac Cardiovasc Surg. 2013;61:578–607.
17. Minegishi Y, Sudoh J, Kuribayasi H, Mizutani H, Seike M, Azuma A, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011;71:70–4.
18. Kenmotsu H, Naito T, Kimura M, Ono A, Shukuya T, Nakamura Y, et al. The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol. 2011;6:1242–6.
19. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest. 2007;132:1652–8.
20. Kumar P, Goldstraw P, Yamada K, Nicholson AG, Wells AU, Hansell DM, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003;125:1321–7.
21. Hoshikawa Y, Kondo T. Perioperative lung injury: acute exacerbation of idiopathic pulmonary fibrosis and acute interstitial pneumonia after pulmonary resection (in Japanese with English abstract). Nihon Geka Gakkai Zasshi (Jpn J Surg). 2004;105:757–62.
22. Sato T, Teramukai S, Kondo H, Watanabe A, Ebina M, Kishi K, et al. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resction for lung cancer. J Thorac Cardiovasc Surg. 2014;147:1604–11.
23. Sugiura H, Takeda A, Hoshi T, Kawabata Y, Sayama K, Jinzaki M, et al. Acute exacerbation of usual interstitial pneumonia after resection of lung cancer. Ann Thorac Surg. 2012;93:937–43.
24. Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg. 2008;34:878–81.
25. Shintani Y, Ohta M, Iwasaki T, Ikeda N, Tomita E, Kawahara K, et al. Predictive factors for postoperative acute exacerbation of interstitial pneumonia combined with lung cancer. Gen Thorac Cardiovasc surg. 2010;58:182–5.
26. Mizuno Y, Iwata H, Shirahashi K, Takamochi K, Oh S, Suzuki K, et al. The importance of intraoperative fluid balance for the prevention of postoperative acute exacerbation of idiopathic pulmonary fibrosis after pulmonary resection for primary lung cancer. Eur J Cardiothorac Surg. 2012;41:e161–5.
27. Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61:980–5.
28. Maniwa T, Isaka M, Nakagawa K, Ohde Y, Okumura T, Endo M, et al. Chest-tube drainage is a sign of acute exacerbation of interstitial lung disease associated with lung cancer. Surg Today. 2013;43:408–11.
29. Maniwa T, Endo M, Isaka M, Nakagawa K, Ohde Y, Okumura T, et al. Acute exacerbation of interstitial lung disease with lung cancer after surgery: evaluation with 2-[18]-fluoro-2-deoxy-d-glucose positron emission tomography. Surg Today. 2014;44:494–8.
30. Watanabe A, Miyajima M, Mishina T, Nakazawa J, Harada R, Kawaharada N, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc surg. 2013;61:254–61.
31. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999;291:367–73.
32. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, CAPACITY Study Group, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760–9.
33. Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35:821–9.
34. Yano M, Sasaki H, Moriyama S, Hikosaka Y, Yokota K, Kobayashi S, et al. Post-operative acute exacerbation of pulmonary fibrosis in lung cancer patients undergoing lung resection. Interact Cardiovasc Thorac Surg. 2012;14:146–50.
35. Ohshimo S, Yokoyama A, Hattori N, Ishikawa N, Hirasawa Y, Kohno N. KL-6, a human MUC1 mucin, promotes proliferation and survival of lung fibroblasts. Biochem Biophys Res Commun. 2005;338:1845–52.
36. Yokoyama A, Kohno N, Hamada H, Sakatani M, Ueda E, Kondo K, et al. Circulating KL-6 predicts the outcome of rapidly progressive idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;158:1680–4.